SCHEMBL29319434

SCHEMBL29319434

COc1ccc(COc2c(F)cc(C(=O)NC[C@]34CC[C@](c5nc(-c6ccnc(S(C)(=O)=O)n6)cs5)(CC3)CC4)c(F)c2F)cc1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.32
CSF1R P07333 1/20 0.32
EGFR P00533 1/20 0.31
CYP3A4 P08684 1/20 0.31
BRAF P15056 1/20 0.31
JAK3 P52333 1/20 0.31
MAPK10 P53779 1/20 0.31
KCNH2 Q12809 1/20 0.31
ERBB4 Q15303 1/20 0.31
CA2 P00918 2/20 0.31
CA4 P22748 2/20 0.31
P2RX7 Q99572 3/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
KAT8 Q9H7Z6 2/20 0.31
DPP4 P27487 1/20 0.31
ROCK2 O75116 1/20 0.30
ROCK1 Q13464 1/20 0.30
KLKB1 P03952 1/20 0.30
ADAM17 P78536 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30995403 1.00 SLC6A9 (0.32) SLC6A9CSF1REGFRCYP3A4BRAF
SCHEMBL29319440 0.89 CSF1R (0.32) CSF1RP2RX7MEN1KMT2ADPP4
SCHEMBL30995334 0.89 CSF1R (0.32) CSF1RP2RX7MEN1KMT2ADPP4
SCHEMBL30995409 0.83 ACHE (0.37)
SCHEMBL29319429 0.83 ACHE (0.37)
SCHEMBL27213785 0.76 P2RX7 (0.40) SLC6A9KCNH2P2RX7KLKB1P2RY12
SCHEMBL27391240 0.76 P2RX7 (0.40) SLC6A9KCNH2P2RX7KLKB1P2RY12
SCHEMBL30995282 0.75 P2RX7 (0.40) SLC6A9KCNH2P2RX7P2RY12
SCHEMBL29318715 0.75 P2RX7 (0.40) SLC6A9KCNH2P2RX7P2RY12
SCHEMBL29317993 0.75 P2RX7 (0.39) SLC6A9KCNH2P2RX7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 SLC6A9 4223/4885CSF1R 4059/4885EGFR 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.